补体因子H变异与子痫前期易感性的鉴定:一项遗传与功能研究
在609例子痫前期病例和2092例对照的病例对照研究中,7例重度子痫前期女性携带5种补体因子H罕见变异,对照中未发现。体外功能与结构分析显示其中4种变异有害,可导致分泌缺陷或补体调节活性受损。
要点
- 7例重度子痫前期女性中鉴定出5种CFH罕见杂合变异,对照中未发现。
- R127H和C1077S可合成但未分泌;R166Q和N1176K分泌正常但C3b结合减少。
- L3V未发现功能缺陷,C1077S和N1176K为新型变异。
核心结论
- 结果提示补体因子H突变导致的补体调节异常是重度子痫前期病理生理机制之一。
研究设计与样本
- 病例对照研究,纳入609例子痫前期病例和2092例对照,来自FINNPEC和国家FINRISK队列。
- 对5种错义变异进行体外补体功能与结构分析,并与野生型比较。
主要发现
- 在7例重度子痫前期女性中鉴定出5种CFH罕见杂合变异(L3V、R127H、R166Q、C1077S和N1176K),对照中未发现。
- C1077S和N1176K为新型变异;抗原性、功能和结构分析确定4种(R127H、R166Q、C1077S和N1176K)为有害。
- R127H和C1077S可合成但未分泌;R166Q和N1176K分泌正常但C3b结合减少,补体调节活性缺陷。
- L3V未发现缺陷。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to investigate the role of genetic variants in complement proteins in pre-eclampsia. DESIGN: In a case-control study involving 609 cases and 2092 controls, five rare variants in complement factor H (CFH) were identified in women with severe and complicated pre-eclampsia. No variants were identified in controls. SETTING: Pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Immune maladaptation, in particular, complement activation that disrupts maternal-fetal tolerance leading to placental dysfunction and endothelial injury, has been proposed as a pathogenetic mechanism, but this remains unproven. POPULATION: We genotyped 609 pre-eclampsia cases and 2092 controls from FINNPEC and the national FINRISK cohorts. METHODS: Complement-based functional and structural assays were conducted in vitro to define the significance of these five missense variants and each compared with wild type. MAIN OUTCOME MEASURES: Secretion, expression and ability to regulate complement activation were assessed for factor H proteins harbouring the mutations. RESULTS: We identified five heterozygous rare variants in complement factor H (L3V, R127H, R166Q, C1077S and N1176K) in seven women with severe pre-eclampsia. These variants were not identified in controls. Variants C1077S and N1176K were novel. Antigenic, functional and structural analyses established that four (R127H, R166Q, C1077S and N1176K) were deleterious. Variants R127H and C1077S were synthesised, but not secreted. Variants R166Q and N1176K were secreted normally but showed reduced binding to C3b and consequently defective complement regulatory activity. No defect was identified for L3V. CONCLUSIONS: These results suggest that complement dysregulation due to mutations in complement factor H is among the pathophysiological mechanisms underlying severe pre-eclampsia.
引用
- Lokki AI, Ren Z, Triebwasser M, et al. Identification of complement factor H variants that predispose to pre-eclampsia: A genetic and functional study. BJOG. 2023. PMID: 37156755. doi:10.1111/1471-0528.17529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。